1. Introduction {#sec1}
===============

SARS-CoV-2 is a novel coronavirus that is responsible for the COVID-19 disease which is a rapidly evolving global pandemic. Coronaviruses primarily target the upper respiratory tract and the lungs, with varying degrees of severity. Related coronaviruses such as the SARS-CoV emerging in China in 2002 and the MERS-CoV in the Middle East in 2012 result in severe respiratory conditions. The SARS-CoV-2 also produces similarly severe respiratory conditions, albeit at a lower rate but with a higher contagion factor \[[@bib1]\]. Alarmingly, infected individuals may be asymptomatic carriers, presumably harboring the viral infection in the upper airway tract, increasing the likelihood of infecting populations that are most susceptible to severe complications \[[@bib2], [@bib3]\].

Although the mechanisms underlying SARS-CoV-2 infection are not completely understood, select human proteins are targets for the virus including ACE2 \[[@bib4]\]. The SARS-CoV-2 receptor binding domain (RBD) interacts strongly with the human ACE2 receptor and TMPRSS2 to enter a human cell \[[@bib5]\]. In addition to ACE2, a recent systems-level analysis of protein-protein interaction with peptides encoded in the SARS-CoV-2 genome identified \~300 additional human proteins, of which, 66 were considered suitable candidates for identification of therapeutics \[[@bib6]\]. Gordon et. al. performed an in vitro assay with human cells expressing 26 SARS-CoV-2 proteins, which was followed by an analysis for high-confidence interactions. Of the 100s of reported interactions 66 were prioritized, and the authors subsequently mined and tested FDA approved drugs that were known or suspected to target these human proteins. Most of the human target proteins are overexpressed in the respiratory tract. Of particular note is the entry receptor ACE2 which is expressed at high levels in a few cell types of the nasal epithelium, as well as elsewhere \[[@bib6], [@bib7]\]. This could be an unusual opportunity for volatile inhaled therapeutics and prophylactics that will have direct access to the cells that are infected by the virus.

The Gordon et al study also identified FDA-approved drugs that have known activity against these human protein targets or are structurally related to chemicals with known activity on the targets. While these drugs have not been comprehensively tested on the virus, another study performed high-throughput testing of \~12,000 FDA-approved or clinical stage drugs on viral replication in cell lines \[[@bib8]\]. This study identified at least 6 potential leads that include a kinase inhibitor, a CCR1 inhibitor and 4 cysteine protease inhibitors that are candidates for testing in clinical trials.

Since the regulatory process for the approval of new drugs can take several years, the repurposing of FDA approved drugs for COVID-19 offers a potential fast-track to approval. One of the more promising candidates being tested is the antiviral Remdesivir, which has been effective in vitro \[[@bib9]\] as well as in non-human primates \[[@bib10]\], with human trails currently ongoing. The other drug being tested is the antimalarial, hydroxychloroquine, which showed some promise alongside the antibiotic, azithromycin, in small clinical trials \[[@bib11], [@bib12]\]. However, hydroxychloroquine has shown less promise in larger trials for treating COVID-19 \[[@bib13]\].

While drug repurposing is expedient, it is possible that drugs designed for other diseases will not be as well suited to respiratory organs, where a large percentage of putative human proteins targeted by the virus are enriched \[[@bib6]\], or to the nervous system, implicated by neurological symptoms as well as prior evidence that coronaviruses can cross the blood brain barrier \[[@bib14], [@bib15]\]. Drug-development strategies are also often guided by minimizing off-target interactions. Repurposed drugs might have to be used in combination, and the side effects and interactions that this entails are presently not well defined. While there are recent efforts exploring novel, directed therapies from small molecule libraries \[[@bib16]\], it is desirable to identify 100--1000s of putative chemicals as the majority may be difficult to synthesize in mass, prove toxic at therapeutic concentrations, or yield inconsistent benefits across patients due to genetic variability. These shortcomings have significantly increased the demand for additional drugs or small molecules that might interfere with viral entry and replication. Additionally, if prophylactics or non-toxic, easy-to-use therapeutics were available even for mild cases that do not require hospitalization and experimental drug treatments, contracting the virus may nevertheless impact long-term health and community transmission \[[@bib17]\].

There are subsequently unmet needs in COVID-19 research, including identification of compounds that target the relevant SARS-CoV-2 human proteins from (1) approved drugs, (2) FDA registered chemicals or (3) a large repository of \~14 million purchasable chemicals from the ZINC 15 database \[[@bib18]\], which we computed additional properties for such as mammalian toxicity, vapor pressure, and logP. For 65 human protein targets that SARS-CoV-2 interacts with that had publicly available bioassay and chemical data \[[@bib6]\], we first generated a database of predictions based on structural similarity to chemicals that interact with the targets and then machine learning models (34). Many chemicals we have identified have little or no known biological activities and are predicted to have low toxicity in addition to a wide range of vapor pressures. These data are a resource to rapidly identify and test novel, safe treatment strategies for COVID-19 and other diseases where the target proteins are relevant.

2. Results {#sec2}
==========

2.1. Identification of important structural features from known inhibitors of human target proteins {#sec2.1}
---------------------------------------------------------------------------------------------------

In order to test whether there is a structural basis for inhibitors of the target proteins identified previously \[[@bib5], [@bib6]\], we used two complementary approaches to evaluate each target\'s training set of compounds with known activity, compiled from the literature. First, we performed an exhaustive search for maximum common substructures among active chemicals. In some cases, enriched substructures were apparent among known ligands, with slight variation in the substructure based on the sensitivity to the targets, suggesting physicochemical features may be relevant in predicting activity against these targets (Supplementary Table 1). Next, we used a machine learning pipeline for predicting chemicals that interfere with SARS-CoV-2 targets. It involves selection of important physicochemical features for each target, followed by fitting support vector machines (SVM) with these features and then evaluating the predictions using various computational validation methods ([Figure 1](#fig1){ref-type="fig"}A). The chemical features that best predicted activity for the different targets included simple 2D information, describing the type and number of bonds, but also more abstract 3D geometries (Tables [1](#tbl1){ref-type="table"} and [2](#tbl2){ref-type="table"}). Identification of each target-specific feature set provides a foundation to better understand the physicochemical basis of the activity. To that end, Supplementary Tables 2-3 include more comprehensive rank ordered lists of the physicochemical features that optimally predict activity against the targets (details about the feature ranking algorithms in Materials and Methods).Figure 1**Machine learning pipeline to identify chemicals that interfere with SARS-CoV-2 targets.a)** Overview of the pipeline to predict chemicals for 65 SARS-CoV-2 human targets selected from Gordon et al., 2020 and using bioassay data from publicly available databases. **b)** Graphically depicts the pipeline details. Available bioassay data on the viral targets were mined for information to use in machine learning or structural analysis. This resulted in 24 targets that could be modeled using values for the most abundant inhibitory assay measure (e.g. K~i~ or IC~50~) and 21 targets modeled by classifying broad inhibition or actvity against the proteins (34 unique targets in total). The remaining targets with limited data were funneled into a structural similarity analysis, which aids in developing more bioassay data and helps clarify the chemical features contributing to bioactivity. For targets modeled with supervised machine learning, optimal chemical features were identified on subsets of training data. The top features were sampled by support vector machines (SVM). These models were then aggregated. In certain cases, the Random Forest algorithm was inlcuded to improve the fit. External chemicals were used to verify successful predictions. Models trained for the 34 targets predicted large chemical databases including FDA registered chemicals and approved drugs, as well as 10+ million purchasable chemicals from the ZINC database. Top scoring predicted chemicals were subsequently assigned theoretical toxicity, log vapor pressure, and MLOGP, which estimates membrane permeability.Figure 1Table 1**Important chemical features for regression models.** Top three physicochemical features for the viral targets with known bioassay activities.Table 1FeatureTargetDescriptionGATS5sABCC1Geary autocorrelation of lag 5 weighted by I-stateRDF055mABCC1Radial Distribution Function - 055/weighted by massSpMax_B(s)ABCC1leading eigenvalue from Burden matrix weighted by I-StateCATS2D_08_AABRD2CATS2D Acceptor-Acceptor at lag 08RDF035sBRD2Radial Distribution Function - 035/weighted by I-stateSpDiam_XBRD2spectral diameter from chi matrixHATS8pBRD4leverage-weighted autocorrelation of lag 8/weighted by polarizabilityR5i+BRD4R maximal autocorrelation of lag 5/weighted by ionization potentialRDF035mBRD4Radial Distribution Function - 035/weighted by massEig02_EA(bo)CSNK2A2eigenvalue n. 2 from edge adjacency mat. weighted by bond orderEig05_EA(bo)CSNK2A2eigenvalue n. 5 from edge adjacency mat. weighted by bond orderSpMax2_Bh(m)CSNK2A2largest eigenvalue n. 2 of Burden matrix weighted by massCATS2D_04_AACSNK2BCATS2D Acceptor-Acceptor at lag 04SHED_DNCSNK2BSHED Donor-NegativeSpMin1_Bh(m)CSNK2Bsmallest eigenvalue n. 1 of Burden matrix weighted by massDISPmDCTPP1displacement value/weighted by massHATS7uDCTPP1leverage-weighted autocorrelation of lag 7/unweightedMor31sDCTPP1signal 31/weighted by I-stateMATS1eDNMT1Moran autocorrelation of lag 1 weighted by Sanderson electronegativityMor23mDNMT1signal 23/weighted by massTDB06uDNMT13D Topological distance based descriptors - lag 6 unweightedGATS4mGFERGeary autocorrelation of lag 4 weighted by massMor14mGFERsignal 14/weighted by massR5iGFERR autocorrelation of lag 5/weighted by ionization potentialDISPpHDAC2displacement value/weighted by polarizabilityIC2HDAC2Information Content index (neighborhood symmetry of 2-order)P_VSA_MR_5HDAC2P_VSA-like on Molar Refractivity, bin 5F04\[C--C\]IMPDH2Frequency of C - C at topological distance 4HOMAIMPDH2Harmonic Oscillator Model of Aromaticity indexVE1_B(s)IMPDH2coefficient sum of the last eigenvector (absolute values) from Burden matrix weighted by I-StateEig02_AEA(dm)ITGB1eigenvalue n. 2 from augmented edge adjacency mat. weighted by dipole momentSHED_AAITGB1SHED Acceptor-AcceptorSpMax2_Bh(s)ITGB1largest eigenvalue n. 2 of Burden matrix weighted by I-stateF10\[C--N\]MARK2Frequency of C - N at topological distance 10nPyrrolesMARK2number of PyrrolesSaaNHMARK2Sum of aaNH E-statesmax_conj_pathMARK3maximum number of atoms that can be in conjugation with each otherSaaNHMARK3Sum of aaNH E-statesVE1_H2MARK3coefficient sum of the last eigenvector (absolute values) from reciprocal squared distance matrixGATS3sNSD2Geary autocorrelation of lag 3 weighted by I-stateHOMANSD2Harmonic Oscillator Model of Aromaticity indexMor16sNSD2signal 16/weighted by I-stateH7mPABPC1H autocorrelation of lag 7/weighted by massJGI7PABPC1mean topological charge index of order 7P_VSA_MR_2PABPC1P_VSA-like on Molar Refractivity, bin 2GATS4mPLATGeary autocorrelation of lag 4 weighted by massMor04sPLATsignal 04/weighted by I-stateR6p+PLATR maximal autocorrelation of lag 6/weighted by polarizabilitynPyrrolesPRKACAnumber of PyrrolesRDF040vPRKACARadial Distribution Function - 040/weighted by van der Waals volumeSpMin3_Bh(m)PRKACAsmallest eigenvalue n. 3 of Burden matrix weighted by massEig02_EA(bo)PSEN2eigenvalue n. 2 from edge adjacency mat. weighted by bond ordernArXPSEN2number of X on aromatic ringVE1sign_D/DtPSEN2coefficient sum of the last eigenvector from distance/detour matrixSHED_DLPTGES2SHED Donor-LipophilicVE2sign_GPTGES2average coefficient of the last eigenvector from geometrical matrixVE3sign_GPTGES2logarithmic coefficient sum of the last eigenvector from geometrical matrixCATS3D_08_ALRIPK1CATS3D Acceptor-Lipophilic BIN 08 (8.000--9.000 Å)MATS5iRIPK1Moran autocorrelation of lag 5 weighted by ionization potentialVE3sign_RGRIPK1logarithmic coefficient sum of the last eigenvector from reciprocal squared geometrical matrixBLTA96SIGMAR1Verhaar Algae base-line toxicity from MLOGP (mmol/l)F10\[C--C\]SIGMAR1Frequency of C - C at topological distance 10TPSA(Tot)SIGMAR1topological polar surface area using N,O,S,P polar contributionsEig01_AEA(dm)TBK1eigenvalue n. 1 from augmented edge adjacency mat. weighted by dipole momentHATS4iTBK1leverage-weighted autocorrelation of lag 4/weighted by ionization potentialSdssCTBK1Sum of dssC E-statesAROMVCParomaticity indexE1mVCP1st component accessibility directional WHIM index/weighted by massMATS5mVCPMoran autocorrelation of lag 5 weighted by massH5sACE2H autocorrelation of lag 5/weighted by I-stateMor10mACE2signal 10/weighted by massMor17mACE2signal 17/weighted by massTable 2**Important chemical features for classification models.** Top three physicochemical features for viral targets where the models classified chemicals as active vs inactive relative to broad inhibition or activition rather than a specific assay value (e.g. K~i~, IC~50~, and AC~50~).Table 2FeatureTargetDescriptionMor18sBRD4signal 18/weighted by I-stateSpMAD_G/DBRD4spectral mean absolute deviation from distance/distance matrixSpMax3_Bh(p)BRD4largest eigenvalue n. 3 of Burden matrix weighted by polarizabilityP_VSA_LogP_3HDAC2P_VSA-like on LogP, bin 3SHED_DAHDAC2SHED Donor-AcceptorSHED_DLHDAC2SHED Donor-LipophilicG(N..N)IDEsum of geometrical distances between N..NSM1_Dz(i)IDEspectral moment of order 1 from Barysz matrix weighted by ionization potentialWapIDEall-path Wiener indexCATS2D_08_DATBK1CATS2D Donor-Acceptor at lag 08F08\[N--N\]TBK1Frequency of N - N at topological distance 8P_VSA_e\_3TBK1P_VSA-like on Sanderson electronegativity, bin 3H7mPRKACAH autocorrelation of lag 7/weighted by massH7sPRKACAH autocorrelation of lag 7/weighted by I-stateRDF060mPRKACARadial Distribution Function - 060/weighted by massGATS6eMARK3Geary autocorrelation of lag 6 weighted by Sanderson electronegativityGATS6mMARK3Geary autocorrelation of lag 6 weighted by massMor02mMARK3signal 02/weighted by massCATS2D_02_DLIMPDH2CATS2D Donor-Lipophilic at lag 02CATS3D_07_DLIMPDH2CATS3D Donor-Lipophilic BIN 07 (7.000--8.000 Å)NaasCIMPDH2Number of atoms of type aasCC-039ABCC1Ar-C(=X)-RVE2sign_Dz(p)ABCC1average coefficient of the last eigenvector from Barysz matrix weighted by polarizabilityVE3sign_Dz(v)ABCC1logarithmic coefficient sum of the last eigenvector from Barysz matrix weighted by van der Waals volumeMor31sABHD12signal 31/weighted by I-stateRTi+ABHD12R maximal index/weighted by ionization potentialVE3sign_Dz(p)ABHD12logarithmic coefficient sum of the last eigenvector from Barysz matrix weighted by polarizabilityE2mBRD22nd component accessibility directional WHIM index/weighted by massGATS2mBRD2Geary autocorrelation of lag 2 weighted by massTDB03iBRD23D Topological distance based descriptors - lag 3 weighted by ionization potentialMAXDPCOMTmaximal electrotopological positive variationnDBCOMTnumber of double bondsP_VSA_MR_2COMTP_VSA-like on Molar Refractivity, bin 2CATS2D_02_ALDNMT1CATS2D Acceptor-Lipophilic at lag 02Mor04sDNMT1signal 04/weighted by I-stateVE3sign_DtDNMT1logarithmic coefficient sum of the last eigenvector from detour matrixChiA_B(i)EIF4Haverage Randic-like index from Burden matrix weighted by ionization potentialF05\[C--O\]EIF4HFrequency of C - O at topological distance 5NaasCEIF4HNumber of atoms of type aasCCENTLOXcentralizationEE_GLOXEstrada-like index (log function) from geometrical matrixVE2_D/DtLOXaverage coefficient of the last eigenvector (absolute values) from distance/detour matrixEta_D\_betaMARK2eta measure of electronic featuresMor29vMARK2signal 29/weighted by van der Waals volumeSpPosA_B(i)MARK2normalized spectral positive sum from Burden matrix weighted by ionization potentialCATS2D_07_ALNEK9CATS2D Acceptor-Lipophilic at lag 07CATS2D_08_ALNEK9CATS2D Acceptor-Lipophilic at lag 08TDB05pNEK93D Topological distance based descriptors - lag 5 weighted by polarizabilityCATS2D_06_DLNEU1CATS2D Donor-Lipophilic at lag 06TDB04iNEU13D Topological distance based descriptors - lag 4 weighted by ionization potentialX3ANEU1average connectivity index of order 3nR06RHOAnumber of 6-membered ringsR8s+RHOAR maximal autocorrelation of lag 8/weighted by I-stateSpMin1_Bh(m)RHOAsmallest eigenvalue n. 1 of Burden matrix weighted by massCATS3D_08_NLSIRT5CATS3D Negative-Lipophilic BIN 08 (8.000--9.000 Å)O-057SIRT5phenol, enol, carboxyl OHSpMax2_Bh(s)SIRT5largest eigenvalue n. 2 of Burden matrix weighted by I-stateCATS2D_04_ALTK2CATS2D Acceptor-Lipophilic at lag 04JGI3TK2mean topological charge index of order 3MATS1iTK2Moran autocorrelation of lag 1 weighted by ionization potentialP_VSA_e\_3VCPP_VSA-like on Sanderson electronegativity, bin 3RDF020pVCPRadial Distribution Function - 020/weighted by polarizabilitySpMaxA_AEA(dm)VCPnormalized leading eigenvalue from augmented edge adjacency mat. weighted by dipole moment

2.2. Machine learning models can successfully predict activity from chemical structure {#sec2.2}
--------------------------------------------------------------------------------------

We identified 24 targets with training sets large enough to model the log IC~50~, K~i~, or AC~50~ ([Figure 2](#fig2){ref-type="fig"}A). Rigorous computational validation was performed and the results on training ([Figure 2](#fig2){ref-type="fig"}B, left) and test data that had been set aside ([Figure 2](#fig2){ref-type="fig"}C, left) indicated good overall performance according to the average mean absolute error (MAE) and the correlation between predicted and observed assay measures (MAE = 0.48; R = 0.62). Predictions of log K~i~ for the viral entry receptor, ACE2, were also accurate (test set R = 0.92; test set mean absolute error (MAE) = 0.53) ([Figure 2](#fig2){ref-type="fig"}C, left; Supplementary Information 1).Figure 2**Models of chemical features accurately predict inhibitors of SARS-CoV-2 targets.a)** Pipeline for fitting and validating models that predict IC~50~, K~i~, or AC~50~ or a classification score, which reflects broad inhibitory activity against the listed viral targets. **b) *Left***, mean absolute error (MAE) in predicting the log transformed endpoints (IC50, Ki, AC50)**. *Right*,** classification of chemicals for broad inhibition or activity against targets, validating using the area under the receiver operating characteristic (ROC) curve (AUC). Plots are for 10-fold cross validation, repeated 5 times. The model predictions are from an ensemble of three support vector machines (SVM), trained on different chemical feature sets or in some cases SVM and Random Forest. c) ***Left***, external test set performance for regression models, where possible. ***Right***, external test set performance for classification models, where possible. More comprehensive performance data in Supplementary Information 1.Figure 2

For some of the viral targets, we noticed that assay data included additional inhibitory measurements or descriptions of general activity against the targets. Some of the available data such as % inhibition, for instance, are less quantitative. However, to include as much of the available data as possible, we created models to identify physicochemical features that might broadly contribute to inhibition or activity against the targets. We therefore assigned binary, active and inactive, labels to the chemicals, then trained models as outlined before ([Figure 2](#fig2){ref-type="fig"}A; Materials and Methods). The models that were developed using this classification approach similarly proved successful, validating over partitions of the training data (avg. AUC = 0.87, avg. Shuffle AUC = 0.50, p \< 10^−19^) ([Figure 2](#fig2){ref-type="fig"}B, right), as well as over sets of external test chemicals (avg. AUC = 0.83, avg. Shuffle AUC = 0.51, p \< 10^−8^) ([Figure 2](#fig2){ref-type="fig"}C, right) (Supplementary Information 1). Collectively, these results suggested the models provided accurate predictions and could be used to screen approved drug libraries as well as databases of commercially available chemicals for novel therapeutics.

2.3. Predicting candidates for repurposing of FDA-approved drugs {#sec2.3}
----------------------------------------------------------------

Repurposing of existing FDA approved drugs offers a path towards rapid deployment of therapeutics against SARS-CoV-2. Approved drugs may have activity that extend beyond the original target protein. Accordingly, we used the machine learning models to predict activities of \~100,000 FDA registered chemicals (UNII database) \[[@bib19]\] as well as the DrugBank \[[@bib20]\] and Therapeutic Targets \[[@bib21], [@bib22]\] databases, which include information on drug interactions, pathways, and approval status. Interestingly, some of the approved drugs are predicted to have high activity against the SARS-CoV-2 targets ([Figure 3](#fig3){ref-type="fig"}A). In order to identify more efficacious candidates, we isolated the drugs scoring in the top 25 for multiple targets and found a few of high priority ([Figure 3](#fig3){ref-type="fig"}B). The structural analysis suggested that hits visually display 2D similarity to known active chemicals as well. (Supplementary Information 2).Figure 3**Approved drugs with putative activity against SARS-CoV-2 targets. a)** The best predicted activity against SARS-CoV-2 targets among databases of approved drugs. Viral targets with few promising candidates are omitted. Comprehensive table in Supplementary Information 2. **b)** Network showing drugs that are among the top 25 for multiple viral targets (drugs: black nodes; viral targets: red nodes).Figure 3

2.4. Predicting volatile drug candidates from a large \~14M chemical space {#sec2.4}
--------------------------------------------------------------------------

Given that many of the human target proteins are overexpressed in the respiratory tract, including the entry receptor ACE2 in only a few cells types of the nasal epithelium, the upper airways and lungs \[[@bib7], [@bib23]\], we reasoned that volatile chemicals may offer a unique opportunity as inhaled therapeutics that will have direct access to the cells and tissues that are infected by the virus. We used the machine learning models to search a large database of \~14 million commercially available chemicals (ZINC) for volatile candidates. We initially isolated the top 1% of the predicted scoring distribution ([Figure 4](#fig4){ref-type="fig"}A, left), which resulted in \>1 million chemicals in total ([Figure 4](#fig4){ref-type="fig"}A, right). To prioritize the hits for potential human use, we next developed machine learning models to predict volatility (vapor pressure) (Supplementary Figure 1) and mammalian toxicity (LD~50~) (Supplementary Figure 2). The toxicity and vapor pressure estimates helped identify smaller priority sets ([Figure 4](#fig4){ref-type="fig"}B). Although the vapor pressures were not especially high, we rank ordered the top candidates according to the best values ([Figure 4](#fig4){ref-type="fig"}C; Supplementary Information 3).Figure 4**Predicting activity against SARS-CoV-2 targets among theoretical volatile chemicals**. **a) *Left***, count of chemicals per target after initially filtering based on predicted scores. ***Right***, chemical counts across all viral targets for the models predicting general inhibitory or activity against (***Classification***) and those for specific inhibitory endpoints (***Regression***) (e.g. IC50). **b)** Pipeline for further prioritizing chemical sets according to estimated log vapor pressure and low mammalian toxicity (LD50). **c)** Top ranking predictions of general inhibition or activity against targets (***Score***) and/or specific inhibitory endpoints (***Predicted Assay Value***) against SARS-CoV-2 targets from the ZINC database, filtered to the highest estimated log vapor pressures.Figure 4

Chemicals with suspected odorant properties, however, represent only a fraction of the chemical space, and these chemicals may not have the activity levels suited for COVID-19 cases. Volatile compounds, for instance, may be biased towards structurally simple chemicals that do not resemble drugs. We therefore also focused on additional chemicals with the high predicted activities for their targets and low estimated toxicities regardless of vapor pressure. We identified numerous candidates with potential activity against multiple viral targets ([Figure 5](#fig5){ref-type="fig"}A) and many other others with significant activity against a single target ([Figure 6](#fig6){ref-type="fig"}A; Supplementary Information 4).Figure 5**Predicted chemicals rank highly for multiple SARS-CoV-2 targets**. **a)** Network of chemicals predicted to have low toxicity that are ranked highly for \>1 viral targets. Chemicals were considered if for multiple viral targets they had \>0.75 activity/class scores or predictions of specific assay measures (K~i~, IC~50~, and AC~50~) \< 100 nM.Figure 5Figure 6**Predictions of SARS-CoV-2 targets among chemicals lacking odorant properties.a)** Sample of ZINC chemicals scoring highly for activity against the viral targets (classification or regression models, Score). Comprehensive tables in Supplementary Information 4, detailing the model type and predicted assay endpoint.Figure 6

3. Discussion {#sec3}
=============

SARS-CoV-2 is a significant world health crisis. The full scope of COVID-19 disease and any long-term health complications following infection remain unclear. Although vaccines are the best long-term solution, treatments will be necessary to mitigate disease severity in the short term. What is concerning is that several repurposed drugs have already been tested in some form of clinical trial, and only one drug Remdesivir has shown a clear benefit in randomized clinical trials. Additionally, there is no guarantee that an effective vaccine can be found for the SARS-CoV-2 virus, and therefore drug candidate pipelines are extremely important to pursue for the long-term research effort against COVID-19. A vaccine against SARS-CoV-2 would likely need to stimulate local immunity, since the infection is limited to mucosal surfaces, and these could be short-lived immunities.

We have therefore taken a comprehensive approach to try and provide a pipeline for short and long-term use, and for a potentially local application route via inhalation. Existing FDA approved drugs that target a single protein important for viral replication and host entry are currently the highest priority for repurposing as new COVID-19 drugs. However, we think that there are compelling reasons to create pipelines to explore many putative targets, and chemical spaces that are far larger and more diverse than the known approved drugs. We have therefore screened \~10+ million potentially purchasable compounds from the ZINC database and also predicted toxicity values for the numerous candidates. In addition, we have identified chemicals that are predicted to affect more than one of the host proteins, suggesting these may have more efficacy. One unusual category we have emphasized is volatiles, as these compounds may be biologically sourced, and therefore microbes could be genetically engineered to produce them in mass \[[@bib24]\]. This would subsequently reduce the strain on global supply chains for chemicals that are necessary in synthesizing certain pharmaceuticals. These chemicals are also intriguing options for drug cocktails. If present in metabolic pathways, they possibly already interact in vivo. Therefore, short-term therapeutic concentrations may be better tolerated in humans.

It is nevertheless important to note that machine learning depends on available data. Because the size and diversity of publicly available bioassay data are limited, caution is required in interpreting the predictions. It is common to find past bioassays focused on similarly shaped chemicals, limiting the scope of the machine learning approach to find new chemistries. Importantly, apart from ACE2, the other human proteins that were identified to interact with SARS-CoV-2 are yet to be tested in vivo for efficacy. And although some of the candidate chemicals we identified may be biologically sourced, the concentrations are not well defined or unknown, nor is there any understanding of a therapeutic concentration in this scenario. These data are presented as a forward-looking resource and a pipeline to evaluate chemical data with additional research. While our motivation was the evolving COVID-19 pandemic, the 65 SARS-CoV-2 targets including ACE2 are relevant to a range of other diseases and conditions. We therefore anticipate that the AI-based predictions of purchasable compounds from 10+ million chemicals will accelerate drug discovery in general and facilitate research on these chemicals in the future for a number of diseases. In general, the use of AI-driven tools could provide additional valuable solutions for tackling Covid-19 \[[@bib25]\].

4. Materials and methods {#sec4}
========================

4.1. Data sources for machine learning {#sec4.1}
--------------------------------------

### 4.1.1. ZINC {#sec4.1.1}

ZINC is a free database comprised of 230 million chemicals for in silico analyses. It was developed as a resource for non-commercial research. Chemicals predicted here are from a purchasable subset; however, availability is subject to change and pricing may vary widely \[[@bib18], [@bib26]\].

### 4.1.2. Bioassay data {#sec4.1.2}

Bioassay data was retrieved from ChEMBL 25 using the associated Python module, which enables access to the API services via Python \[[@bib27], [@bib28]\]. The various inhibitory measures/endpoints, wherever possible, are standardized to nM units; the logarithm of the standardized values was used for machine learning. Regression models were fit for a single endpoint. For classification machine learning models, however, 'active' class chemicals were defined using the deposited activity comments such as for assays of general activity against proteins, and added active labels for endpoints with values up to 10,000 nM (K~i~ and IC~50~) and for the semi-quantitative % inhibition, greater than 10%. The majority class was downsampled during the training and model tuning phases to adjust for possible class imbalances. Because the class labels were assigned using arbitrary cutoffs and the predicted activities for classification models from various assay endpoints are not clearly defined, we also compared each model fit to shuffled labels. Training for the regression and classification approaches was done on 85% of the total data. Notably, in a small number of cases the remaining 15% was insufficient to effectively estimate performance using an external test set. To reduce bias, feature selection (recursive feature elimination (RFE) algorithm) was always run on 85% of the data over 250--300 different partitions (iteratively running the 10-fold cross validation 25--30 times). However, for these cases, the held-out portion (15%) was then incorporated back into the dataset to better estimate performance of the trained model by 10-fold cross-validation (repeated 5 times) and obtain a better fit. We also fit 3 different radial basis function (RBF) support vector machine (SVM) models, wherein the chemical features (predictors) were randomly sampled (50%) from the top 70. This makes the performance estimates more conservative (see Key Resources Table for machine algorithm source files). However, the structural diversity and size of the datasets imply some bias in the performance estimates.

### 4.1.3. Toxicity data {#sec4.1.3}

Training and testing data are curated by various government agencies and provided freely to the general public as databases (see Key Resources Table) \[[@bib29], [@bib30], [@bib31]\].

### 4.1.4. Vapor pressure data {#sec4.1.4}

Training and testing data are from EPI Suite \[[@bib32]\], which is developed and maintained by the Environmental Protection Agency (EPA) (see Key Resources Table). Methods for fitting these models are as outlined in the [Figure 1](#fig1){ref-type="fig"} pipeline. To compare the vapor pressure model predictions with respect to different machine learning methods as well as EPI suite, data were split into train/test partitions as defined in a previous study \[[@bib33]\].

4.2. Selecting optimally predictive chemical features {#sec4.2}
-----------------------------------------------------

### 4.2.1. Optimizing chemical structures {#sec4.2.1}

Chemical features were computed with \~5300 AlvaDesc descriptors, from the developers of DRAGON software, and 3D coordinates and optimization performed using RDKit in Python \[[@bib34]\].

### 4.2.2. Chemical feature ranking and importance {#sec4.2.2}

#### 4.2.2.1. Cross-validated recursive feature elimination (CV-RFE) {#sec4.2.2.1}

Recursive feature elimination iteratively selects subsets of features to identify optimal sets. The algorithm is a "wrapper" and therefore relies on an additional algorithm to supply predictions and quantify importance. We used two different algorithms, depending on the size and composition of data: (1) Random Forest and (2) Support Vector Machine (SVM). Random forest determines the importance in relation to the % increase in error when permuting a feature or predictor. There is no equivalent method for computing importance with the SVM. Accordingly, the importance is based on fitting a model between the response and each predictor or feature as compared to null. If the response is numeric, importance is derived from the pseudo R^2^ (non-linear regression). If, however, the response is binary, the AUC is instead computed for each predictor or feature (see Key Resources Table for algorithm source files).

Including cross-validation with the recursive feature elimination (RFE) partitions the training data into multiple folds. This step avoids biasing performance estimates but results in lists of top predictors over the cross-validation folds such that importance of a predictor is based on a selection rate.

#### 4.2.2.2. Selection bias {#sec4.2.2.2}

Selecting features or predictors on the same dataset used for cross validation results in models that have already "seen" possible partitions of the data and therefore performance metrics will be biased. Selection bias \[[@bib35]\] was addressed by bootstrapping and cross validation, which ensure some separation between predictor/feature selection and model-fitting/validation. In addition to these methods, we used hidden test sets or more generally performed the feature selection on a portion of the data.

4.3. Selecting optimal machine learning algorithms {#sec4.3}
--------------------------------------------------

The support vector machine (SVM) with the radial basis function kernel (RBF) outperformed regularized Random Forest (regRF) or performed comparably. Rather than utilize many different approaches, we aggregated multiple SVM models to improve generalizability. However, in the case of the classification model for EIF4H, we included the regularized random forest algorithm, as the aggregated prediction (SVM and regRF) was clearly optimal on the test data. Algorithm selection and training was done using the classification and regression training package in R \[[@bib36]\], caret \[[@bib37]\], and the implementation of the Support Vector Machine (SVM) algorithm in Kernlab \[[@bib38]\].

4.4. Enriched substructures/cores {#sec4.4}
---------------------------------

Enriched cores were analyzed using RDKit through Python \[[@bib34]\]. The algorithm performs an exhaustive search for maximum a common substructure among a set of chemicals. In practice, larger sets often yield fewer substantive cores. To remedy this, the algorithm includes a threshold parameter that relaxes the proportion of chemicals containing the core. We used a threshold of 0.55, which ensures that the majority of the chemicals contained the core.

4.5. Chemical fingerprinting {#sec4.5}
----------------------------

Extended Connectivity Fingerprints (ECFP) are a class of cheminformatic algorithms that iteratively combine chemical features that are present within a predefined radius/diameter, representing them by a set of integer values. Typically, the fingerprint is converted into a binary string of fixed length using a hash function. Here, the bit length was set at 1024 and a radius of 2 (diameter = 4 or ECFP4). This structural representation was preferred as it is strongly associated with activity \[[@bib39]\]. Accordingly, it is a suitable alternative to identify drug candidates in the absence of machine learning models. We used the ECFP algorithm in RDKit (Morgan or circular fingerprint) \[[@bib34]\]. The similarity between the fingerprints of chemicals with known activity against the SARS-CoV-2 targets and prospective chemicals was computed using the Tanimoto index. This index is a similarity coefficient (0--1; 1 = max similarity). It is the overlap of the "on-bits" divided by the sum of the unique "on-bits". Notably, coefficients of 1 need not imply identical chemicals.$$sim{\left( {AB} \right) = \frac{c}{a + b - c}}$$*where c = overlapping "on-bits"; a = "on bits" in A; b = "on-bits" in B*.

4.6. Support vector machine (SVM) {#sec4.6}
---------------------------------

Training the support vector machine (SVM) involves identifying a set of parameters that optimize a cost function, where cost 1 and cost 0 correspond to training chemicals labeled as "Active" and "Inactive," respectively. θ^T^ is the scoring function or output of the support vector machine. If the output is ≥0, the prediction is "Active." The function (ƒ) is a kernel function.$$SVMCost = \underset{\theta}{\min C}\sum\limits_{i = 1}^{m}y^{(i)}cost_{1}\left( {\theta^{T}f^{(i)}} \right) + \left( {1 - y^{(i)}} \right)cost_{\text{0}}\left( {\theta^{T}f^{(i)}} \right) + \frac{1}{2}\sum\limits_{j = 1}^{n}\theta_{j}^{2}$$

The kernel determines the shape of the decision boundary between the active and inactive chemicals from the training set. The radial basis function (RBF) or Gaussian kernel enables the learning of more complex, non-linear boundaries. It is therefore well suited for problems in which the biologically active chemicals cannot be properly classified as a linear function of physicochemical properties. This kernel computes the similarity for each chemical (*x*) and a set of landmarks (*l*), where σ^2^ is a tunable parameter determined by the problem and data. The similarity with respect to these landmarks is used to predict new chemicals ("Active" vs. "Inactive").$$Gaussian\ Kernel = \text{exp}\left( \frac{- \left( {x - l^{(1)}} \right)^{2}}{2\sigma^{2}} \right)$$

### 4.6.1. Model performance metrics {#sec4.6.1}

The Area under the ROC Curve (**AUC**) assesses the true positive rate (TPR or sensitivity) as a function of the false positive rate (FPR or 1-specificity) while varying the probability threshold (T) for a label (Active/Inactive). If the computed probability score (x) is greater than the threshold (T), the observation is assigned to the active class. Integrating the curve provides an estimate of classifier performance, with the top left corner giving an AUC of 1.0 denoting maximum sensitivity to detect all targets or actives in the data without any false positives. The theoretical random classifier is reported at AUC = 0.5.$$TPR\left( T \right) = {\int_{T}^{\infty}{f_{1}\left( x \right)dx}}$$$$FPR\left( T \right) = {\int_{T}^{\infty}{f_{\text{0}}\left( x \right)dx}}$$where T is a variable threshold and x is a probability score.

However, we generated classifiers that are more authentic than theoretical random classification, shuffling the chemical feature values in the models and statistically comparing the mean AUCs across multiple partitions of the data. This controls against optimally tuned algorithms predicting well simply because of specific predictor attributes (e.g. range, mean, median, and variance) or models that are of a specific size (number of predictors) performing well even with shuffled values. Additionally, biological data sets are often small, with stimuli or chemicals that---rather than random selection---reflect research biases, possibly leading to optimistic validation estimates without the proper controls.

We used the AUC for evaluating classification models. For the classification-based training, we initially converted the inhibitory data into a binary label (Active/Inactive). For predictions of quantitative bioassay measures (e.g. K~i~, IC~50~, AC~50~, Log LD~50~), we computed the mean absolute error (MAE), the correlation coefficient (R) and the squared correlation coefficient (R2). **MAE:** Mean absolute error is the mean of the absolute difference between predicted and observed (% usage). It therefore assigns equal weight to all prediction errors, whether large or small.$$\text{MAE} = {\frac{1}{n}\sum_{i = 1}^{n}\left( {y - y} \right)}$$where, $y$ = predicted and $y$ = observed$$\text{Sensitivity} = \frac{TP}{TP + FN}$$where, TP = True Positive and FN = False Negative$$\text{Specificity} = \frac{TN}{TN + FP}$$where, TN = True Negative and FP = False Positive.KEY RESOURCES TABLEReagent or ResourceSourceIdentifierDeposited DataZINC 15Sterling and Irwin, 2015<https://zinc.docking.org/substances/home/>chEMBL 25EMBL-EBI, 2011; Mendez et al., 2019<https://www.ebi.ac.uk/chembl/>EPI Suite DataEPA, 2015<http://esc.syrres.com/interkow/EPiSuiteData.htm>DrugBankWishart et al., 2018<https://www.drugbank.ca/>Therapeutic Targets Database (TTD)Chen, 2002; Zhu et al., 2009<http://db.idrblab.net/ttd/>FDA: Substance Registration Database (FDA UNII)FDA, 2020<https://fdasis.nlm.nih.gov/srs/>Hazardous Substances Data Bank (HSDB)Fonger et al., 2014<https://www.nlm.nih.gov/databases/download/hsdb.html>Viral TargetsGordon et al. 2020<https://www.nature.com/articles/s41586-020-2286-9>AcutoxbaseKinsner-Ovaskainen et al., 2009<https://www.acutetox.eu/>DSSToxRichard and Williams, 2002<https://www.epa.gov/chemical-research/distributed-structure-searchable-toxicity-dsstox-database>Top 50 physicochemical features to predict inhibitory assay activity for each SARS-CoV-2 targetThis paperSupplementary Table 2Top 50 physicochemical features to predict broadly inhibiting activity for each SARS-CoV-2 targetThis paperSupplementary Table 3Top predicted drug and FDA registered chemicals.\
Structural similarity between drugs and chemicals with bioassay activities for SARS-CoV-2 targetsThis paperSupplementary Information 2Top predicted chemicals from ZINC, rank ordered by estimated vapor pressureThis paperSupplementary Information 3Top predicted chemicals from ZINC, filtered for toxicityThis paperSupplementary Information 4Software and AlgorithmsClassification and regression training (caret)Kuhn, 2008<https://github.com/topepo/caret>KernlabKaratzoglou et al., 2004<https://github.com/cran/kernlab>Regularized Random Forest (RRF)Deng and Runger, 2013<https://github.com/softwaredeng/RRF>RDKitLandrum, 2006\
Python wrapper<https://github.com/rdkit/rdkit>ggplot2Wickham, 2016<https://github.com/tidyverse/ggplot2>
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Appendix A. Supplementary data {#appsec1}
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The following is the supplementary data related to this article:**Supplementary_Figure_1a)** Ensemble model for predicting log vapor pressure is validated on 676 test chemicals. Test set predictions are bootstrapped 500 times, averaged over 100 bins (5 bootstrap samples per bin). Predictive success is quantified as the mean absolute error (MAE), with the test set value reported in the plot area.**b**) The test chemical predictions are assessed using the R2 value, bootstrapped 500 times and averaged over 100 bins (5 bootstrap samples per bin). Overall R2 value reported in the plot area. Individual models are trained on different chemical feature sets and predictions are aggregated.Supplementary_Figure_2**a)** Ensemble model prediction of rat log LD~50~ for 2895 test chemicals. Relationship between predicted and observed log LD~50~ is quantified as the correlation. Value reported in plot area.Supplementary_Figure_2Supplementary_Information_1Validation statistics using classification and regression-based support vector machine (SVM) models to predict inhibitory activity against SARS-CoV-2 targets. **Sheet 1**: Test set performance for classification-based models. Models are compared to an otherwise identical model where the training was performed on shuffled or permuted classification labels. P-values are based on a One-tailed Independent Samples T-test over 500 bootstrap iterations. Where possible, exact p-values are reported. **Sheet 2**: raw data for the Sheet 1 analysis. **Sheet 3**: Contains test set performance details for regression-based models. **Sheet 4**: Predictions of drugs provided in the supplementary information of Gordon et. al. (2020). These are expert curated and approved/investigational compounds with reported activities against select SARS-CoV-2 targets. Explanations and formulae for model performance metrics are in Materials and Methods.Supplementary_Information_1Supplementary_Information_2Machine learning predictions of SARS-CoV-2 targets for the DrugBank and Therapeutic Targets databases (**Sheet 1; Sheet 2**). Machine learning predictions of SARS-CoV-2 targets for the FDA UNII database (**Sheet 3; Sheet 4**). Structural similarity analysis (**Sheet 5**), which applies a fingerprint (circular or Morgan) approach to identify basic structural overlap between chemicals with known activity against the SARS-CoV-2 targets and drugs as well as other chemicals in the UNII database such as food additives. The similarity coefficient (Tanimoto) is on the scale 0--1 (1 = max similarity). The "DB" column is the database ID or name of the chemical that is compared to the \>10, 000 chemicals in assays for the SARS-CoV-2 targets. Data are filtered to reflect the highest similarities.Supplementary_Information_2\_FiltSupplementary_Information_3The best candidates included in the ZINC database with the largest predicted log vapor pressure values.Supplementary_Information_3\_FiltSupplementary_Information_4Top machine learning predictions for SARS-CoV-2 targets, filtered with respect to theoretical LD50 values and without regard for vapor pressure.Supplementary_Information_4\_FiltSupplementary Table_1Enriched substructures/cores among assay chemicals for different measures, standardized to nanomolar units (nM). Three broad concentration ranges are used to isolate more interesting enriched features with respect to different sensitivities for the viral targets. Images of representative chemicals are shown for each target. Bonds and atoms appear in black. The enriched substructure is in red. GT = greater than; LT = less than; LTE = less than or equal to.Supplementary_Table_1Supplementary Table 2Top 50 physicochemical features for predict raw assay activity for the protein targets (regression). The SVM models in [Figure 2](#fig2){ref-type="fig"} sample these features.Supplementary Table 2Supplementary Table 3Top 50 physicochemical features to predict classification labels for the protein targets (classification). The classification labels here reflect broad inhibition. SVM models in [Figure 2](#fig2){ref-type="fig"} sample these features.Supplementary Table 3
